JP2013510900A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013510900A5 JP2013510900A5 JP2012539451A JP2012539451A JP2013510900A5 JP 2013510900 A5 JP2013510900 A5 JP 2013510900A5 JP 2012539451 A JP2012539451 A JP 2012539451A JP 2012539451 A JP2012539451 A JP 2012539451A JP 2013510900 A5 JP2013510900 A5 JP 2013510900A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- aryl
- hydroxy
- heterocyclyl
- alkoxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000000217 alkyl group Chemical group 0.000 claims 32
- 150000001875 compounds Chemical class 0.000 claims 23
- 125000003118 aryl group Chemical group 0.000 claims 22
- 125000003545 alkoxy group Chemical group 0.000 claims 20
- 125000000623 heterocyclic group Chemical group 0.000 claims 18
- 229910052739 hydrogen Inorganic materials 0.000 claims 18
- 239000001257 hydrogen Substances 0.000 claims 18
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 18
- 208000027866 inflammatory disease Diseases 0.000 claims 18
- 229910052736 halogen Inorganic materials 0.000 claims 16
- 150000002367 halogens Chemical class 0.000 claims 16
- 150000002431 hydrogen Chemical class 0.000 claims 11
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 9
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 8
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 7
- 102100037850 Interferon gamma Human genes 0.000 claims 7
- 108010074328 Interferon-gamma Proteins 0.000 claims 7
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 7
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 7
- 125000003710 aryl alkyl group Chemical group 0.000 claims 6
- 230000001404 mediated effect Effects 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 6
- 239000012453 solvate Substances 0.000 claims 6
- 239000000651 prodrug Substances 0.000 claims 5
- 229940002612 prodrug Drugs 0.000 claims 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims 4
- 108010002350 Interleukin-2 Proteins 0.000 claims 4
- 108090001005 Interleukin-6 Proteins 0.000 claims 4
- 125000004104 aryloxy group Chemical group 0.000 claims 4
- -1 hydroxy, amino Chemical group 0.000 claims 4
- 201000008482 osteoarthritis Diseases 0.000 claims 4
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims 3
- 208000024827 Alzheimer disease Diseases 0.000 claims 3
- 206010009900 Colitis ulcerative Diseases 0.000 claims 3
- 102000004127 Cytokines Human genes 0.000 claims 3
- 108090000695 Cytokines Proteins 0.000 claims 3
- 108090001007 Interleukin-8 Proteins 0.000 claims 3
- 108010063738 Interleukins Proteins 0.000 claims 3
- 102000015696 Interleukins Human genes 0.000 claims 3
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 3
- 229960003130 interferon gamma Drugs 0.000 claims 3
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 208000006386 Bone Resorption Diseases 0.000 claims 2
- 201000003874 Common Variable Immunodeficiency Diseases 0.000 claims 2
- 208000011231 Crohn disease Diseases 0.000 claims 2
- 206010061598 Immunodeficiency Diseases 0.000 claims 2
- 208000029462 Immunodeficiency disease Diseases 0.000 claims 2
- 206010061218 Inflammation Diseases 0.000 claims 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 2
- 208000003456 Juvenile Arthritis Diseases 0.000 claims 2
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims 2
- 208000034578 Multiple myelomas Diseases 0.000 claims 2
- 208000014767 Myeloproliferative disease Diseases 0.000 claims 2
- 208000001132 Osteoporosis Diseases 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 2
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 2
- 206010040070 Septic Shock Diseases 0.000 claims 2
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims 2
- 230000024279 bone resorption Effects 0.000 claims 2
- 208000019069 chronic childhood arthritis Diseases 0.000 claims 2
- 230000001684 chronic effect Effects 0.000 claims 2
- 230000007813 immunodeficiency Effects 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- 229940047122 interleukins Drugs 0.000 claims 2
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 230000000306 recurrent effect Effects 0.000 claims 2
- 208000030507 AIDS Diseases 0.000 claims 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000009137 Behcet syndrome Diseases 0.000 claims 1
- 206010006895 Cachexia Diseases 0.000 claims 1
- 201000009273 Endometriosis Diseases 0.000 claims 1
- 206010014824 Endotoxic shock Diseases 0.000 claims 1
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 claims 1
- 208000031886 HIV Infections Diseases 0.000 claims 1
- 208000037357 HIV infectious disease Diseases 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 208000030289 Lymphoproliferative disease Diseases 0.000 claims 1
- 201000009906 Meningitis Diseases 0.000 claims 1
- 201000007224 Myeloproliferative neoplasm Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 208000007452 Plasmacytoma Diseases 0.000 claims 1
- 206010063837 Reperfusion injury Diseases 0.000 claims 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 206010053613 Type IV hypersensitivity reaction Diseases 0.000 claims 1
- 206010046851 Uveitis Diseases 0.000 claims 1
- 206010047115 Vasculitis Diseases 0.000 claims 1
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 1
- 201000009961 allergic asthma Diseases 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 206010002022 amyloidosis Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 208000017760 chronic graft versus host disease Diseases 0.000 claims 1
- 208000029078 coronary artery disease Diseases 0.000 claims 1
- 230000003111 delayed effect Effects 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 208000010710 hepatitis C virus infection Diseases 0.000 claims 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims 1
- 230000009610 hypersensitivity Effects 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 208000012947 ischemia reperfusion injury Diseases 0.000 claims 1
- 201000001268 lymphoproliferative syndrome Diseases 0.000 claims 1
- 201000004792 malaria Diseases 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 1
- 230000036303 septic shock Effects 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- 230000008733 trauma Effects 0.000 claims 1
- 230000005951 type IV hypersensitivity Effects 0.000 claims 1
- 208000027930 type IV hypersensitivity disease Diseases 0.000 claims 1
- 0 CCNC(CCC*CC(C(CC(*)=*)*12C3*C1C2*3)C1(*)CC1)C(CC*=C)*1*C1 Chemical compound CCNC(CCC*CC(C(CC(*)=*)*12C3*C1C2*3)C1(*)CC1)C(CC*=C)*1*C1 0.000 description 3
- DGRLAPOMRSTBKD-RIDBUNHASA-N CCC(C(C(C)C/C(/C)=C/C=C/C(C(C(C)C(C(C)/C(/C=C/C(C)C(/C=C/C)O)=N/OC)O)OC(/C(/OC)=C/C(/C)=C/C1C)=O)OC)O)C1O Chemical compound CCC(C(C(C)C/C(/C)=C/C=C/C(C(C(C)C(C(C)/C(/C=C/C(C)C(/C=C/C)O)=N/OC)O)OC(/C(/OC)=C/C(/C)=C/C1C)=O)OC)O)C1O DGRLAPOMRSTBKD-RIDBUNHASA-N 0.000 description 1
- MQVXRKBZLNXSGW-GHKBDNCUSA-N CCC(C(C)/C(/C=C/C1C)=N/OC[NH+]([O-])OC1C#C)O Chemical compound CCC(C(C)/C(/C=C/C1C)=N/OC[NH+]([O-])OC1C#C)O MQVXRKBZLNXSGW-GHKBDNCUSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26181009P | 2009-11-17 | 2009-11-17 | |
| US61/261,810 | 2009-11-17 | ||
| PCT/IB2010/055162 WO2011061667A1 (en) | 2009-11-17 | 2010-11-15 | Use of macrocyclic lactone derivatives for the treatment of inflammatory disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013510900A JP2013510900A (ja) | 2013-03-28 |
| JP2013510900A5 true JP2013510900A5 (enExample) | 2014-01-09 |
Family
ID=43502636
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012539451A Pending JP2013510900A (ja) | 2009-11-17 | 2010-11-15 | 炎症性疾患治療のための大環状ラクトン誘導体の使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20120225889A1 (enExample) |
| EP (1) | EP2501378A1 (enExample) |
| JP (1) | JP2013510900A (enExample) |
| AU (1) | AU2010320558A1 (enExample) |
| CA (1) | CA2780912A1 (enExample) |
| IL (1) | IL219806A0 (enExample) |
| NZ (1) | NZ600662A (enExample) |
| WO (1) | WO2011061667A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2012005618A (es) * | 2009-11-17 | 2012-08-15 | Piramal Life Sciences Ltd | Derivados de lactona macrociclica para el tratamiento del cancer. |
| EP2809660B1 (en) * | 2012-02-02 | 2016-01-20 | Ensemble Therapeutics Corporation | Macrocyclic compounds for modulating il-17 |
| WO2014118740A1 (en) * | 2013-02-04 | 2014-08-07 | Piramal Enterprises Limited | Macrocyclic lactone derivatives and uses thereof |
| DE102017003725A1 (de) | 2017-04-18 | 2018-10-18 | Olaf Weber | Anti-VEGF- und anti-C5-Antikörper zur Behandlung der equinen rezidivierenden Uveitis |
| US11339111B2 (en) | 2017-11-30 | 2022-05-24 | Societe Des Produits Nestle S.A. | Polyketide compound and derivatives thereof for use in the prevention and treatment of a neurological disorder |
| CN116745276A (zh) * | 2020-12-16 | 2023-09-12 | 密歇根大学董事会 | Nef下调抑制剂 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0639644A1 (de) * | 1993-08-16 | 1995-02-22 | Ciba-Geigy Ag | Neue Makrolide und ihre Verwendung |
| CA2152765A1 (en) * | 1994-06-30 | 1995-12-31 | Jeroen Elisabeth-Joseph Knops | Methods for treating a physiological disorder associated with beta amyloid peptide |
| US20070105791A1 (en) * | 2002-07-29 | 2007-05-10 | Optimer Pharmaceuticals, Inc. | Method of treating clostridium difficile-associated diarrhea |
| TR201902533T4 (tr) * | 2004-05-14 | 2019-03-21 | Merck Sharp & Dohme | Antibiyotiklerin kullanımı ile bağdaştırılan hastalıkların tedavisi. |
| WO2009141786A2 (en) * | 2008-05-21 | 2009-11-26 | Piramal Life Sciences Limited | Anti-inflammatory compounds |
| MX2012005618A (es) * | 2009-11-17 | 2012-08-15 | Piramal Life Sciences Ltd | Derivados de lactona macrociclica para el tratamiento del cancer. |
-
2010
- 2010-11-15 US US13/510,552 patent/US20120225889A1/en not_active Abandoned
- 2010-11-15 JP JP2012539451A patent/JP2013510900A/ja active Pending
- 2010-11-15 AU AU2010320558A patent/AU2010320558A1/en not_active Abandoned
- 2010-11-15 NZ NZ600662A patent/NZ600662A/en not_active IP Right Cessation
- 2010-11-15 CA CA2780912A patent/CA2780912A1/en not_active Abandoned
- 2010-11-15 WO PCT/IB2010/055162 patent/WO2011061667A1/en not_active Ceased
- 2010-11-15 EP EP10798382A patent/EP2501378A1/en not_active Withdrawn
-
2012
- 2012-05-15 IL IL219806A patent/IL219806A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013510900A5 (enExample) | ||
| HRP20120900T1 (hr) | Inhibitori p38 kinaze bazirani na peteroäślanom heterociklu | |
| JP2017512186A5 (enExample) | ||
| RU2330858C2 (ru) | Новые соединения, составы и способы лечения воспалительных заболеваний и состояний | |
| JP2015502387A5 (enExample) | ||
| JP2018158926A5 (enExample) | ||
| JP2020537657A5 (enExample) | ||
| JP2014505032A5 (enExample) | ||
| JP2019530699A5 (enExample) | ||
| JP2019501927A5 (enExample) | ||
| AR040803A1 (es) | Ligandos de receptores canabinoides, composiciones farmaceuticas, un proceso para su elaboracion y el uso de dichos compuestos, solos o combinados, para la preparacion de medicamentos | |
| RU2015137757A (ru) | Производные пиридазинон-амидов | |
| JP2006510676A5 (enExample) | ||
| RU2007102576A (ru) | Новые индаэолкарбоксамиды и их применение | |
| JP2017504650A5 (enExample) | ||
| CN111989332A (zh) | 作为cdk抑制剂的大环化合物、其制备方法及其在医药上的应用 | |
| UA73553C2 (en) | Piperazine derivatives | |
| JP2013518888A5 (enExample) | ||
| JP2010523722A5 (enExample) | ||
| RU2008137086A (ru) | Борсодержащие малые молекулы в качестве противовоспалительных средств | |
| JP2009537603A (ja) | ５−アミノ−３−（２’，３’−ジ−Ｏ−アセチル−ベータ−Ｄ−リボフラノシル）−３Ｈ−チアゾロ［４，５−ｄ］ピリミジン−２−オンのマレイン酸塩のＡ型及びＢ型結晶形 | |
| JP2005513125A5 (enExample) | ||
| JP2016510323A5 (enExample) | ||
| JP2007522142A5 (enExample) | ||
| JP2018526421A5 (enExample) |